About VIVITRA TRASTUZUMAB INJECTION
Vivitra
Specifications:-
- Brand Name :- VIVITRA
- Content:- Trastuzumab Lyophilized
- Strength: 440 MG
- Form:- VIAL
- Packing:- 1 Vial with 20 ml
- Manufactured By :- Zydus
Note :- VIVITRAIs A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug..............
Precise Treatment for HER2-Positive CancersVivitra Trastuzumab offers targeted therapy for patients diagnosed with HER2-overexpressing breast cancer and metastatic gastric cancer. As a monoclonal antibody, it binds specifically to the HER2 receptor, interrupting cancer cell growth and proliferation. Its role as an antineoplastic agent enhances treatment outcomes, especially when administered in conjunction with other chemotherapeutic agents.
Special Handling and Administration GuidelinesBefore infusion, Vivitra Trastuzumab must be reconstituted using sterile water for injection. The medication is administered intravenously under the supervision of skilled healthcare professionals to ensure optimal safety and efficacy. It comes in single-vial packaging and is strictly to be prescribed by a qualified physician, following recommended dosing protocols.
Storage and Shelf Life AssuranceVivitra Trastuzumab should be stored in a refrigerator at temperatures between 2C8C, avoiding freezing. With a shelf life of 24 months from the date of manufacture, proper storage helps maintain the biologic integrity and effectiveness of the medicine throughout its use period.
FAQs of VIVITRA TRASTUZUMAB INJECTION:
Q: How should Vivitra Trastuzumab Injection be prepared and administered?
A: Vivitra requires reconstitution with sterile water for injection and must be administered as an intravenous infusion by trained healthcare professionals in a clinical setting.
Q: What conditions is Vivitra Trastuzumab indicated for?
A: Vivitra is prescribed for the treatment of HER2-overexpressing breast cancer and metastatic gastric cancer in adult patients, providing targeted therapy as a biologic anticancer agent.
Q: When is Vivitra Trastuzumab typically given during cancer treatment?
A: The injection is commonly initiated with an 8 mg/kg dose, followed by 6 mg/kg every three weeks, according to the physicians plan and individual patient response.
Q: Where should Vivitra Trastuzumab be stored for optimal efficacy?
A: The product should be kept in a refrigerator at 2C8C and must not be frozen to preserve its quality and effectiveness throughout the shelf life.
Q: What are the potential side effects of using Vivitra Trastuzumab?
A: Some known side effects include fever, chills, infusion reactions, and cardiac dysfunction. All adverse events should be reported to the healthcare provider immediately.
Q: What is the benefit of choosing Vivitra Trastuzumab for cancer treatment?
A: Vivitra targets the HER2 receptor, offering a precise approach to slow cancer progression, especially in patients whose tumors overexpress HER2, improving treatment efficacy.
Q: Is Vivitra Trastuzumab suitable for all patients?
A: Vivitra is recommended only for adult patients with HER2-positive cancers and should not be used without a physicians prescription due to potential risks and specific administration requirements.